Blueprint Medicines Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Kate Haviland
Chief executive officer
US$6.2m
Total compensation
CEO salary percentage | 11.3% |
CEO tenure | 2yrs |
CEO ownership | 0.1% |
Management average tenure | 3.6yrs |
Board average tenure | 9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$507m |
Sep 30 2023 | n/a | n/a | -US$555m |
Jun 30 2023 | n/a | n/a | -US$554m |
Mar 31 2023 | n/a | n/a | -US$581m |
Dec 31 2022 | US$6m | US$701k | -US$558m |
Sep 30 2022 | n/a | n/a | -US$718m |
Jun 30 2022 | n/a | n/a | -US$702m |
Mar 31 2022 | n/a | n/a | -US$650m |
Dec 31 2021 | US$4m | US$501k | -US$644m |
Sep 30 2021 | n/a | n/a | -US$411m |
Jun 30 2021 | n/a | n/a | US$340m |
Mar 31 2021 | n/a | n/a | US$325m |
Dec 31 2020 | US$2m | US$461k | US$314m |
Sep 30 2020 | n/a | n/a | US$333m |
Jun 30 2020 | n/a | n/a | -US$395m |
Mar 31 2020 | n/a | n/a | -US$371m |
Dec 31 2019 | US$3m | US$432k | -US$348m |
Sep 30 2019 | n/a | n/a | -US$362m |
Jun 30 2019 | n/a | n/a | -US$340m |
Mar 31 2019 | n/a | n/a | -US$267m |
Dec 31 2018 | US$3m | US$393k | -US$237m |
Sep 30 2018 | n/a | n/a | -US$205m |
Jun 30 2018 | n/a | n/a | -US$170m |
Mar 31 2018 | n/a | n/a | -US$177m |
Dec 31 2017 | US$1m | US$353k | -US$148m |
Compensation vs Market: Kate's total compensation ($USD6.22M) is above average for companies of similar size in the German market ($USD3.35M).
Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.
CEO
Kate Haviland (47 yo)
2yrs
Tenure
US$6,217,694
Compensation
Ms. Kathryn Haviland, also known as Kate, is Director of Bicara Therapeutic, Inc. from October 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serves as President, Chie...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2yrs | US$6.22m | 0.098% $ 5.2m | |
Co-Founder & Director | no data | US$323.52k | 0.11% $ 6.0m | |
Chief Financial Officer | 8.2yrs | US$2.36m | 0.026% $ 1.4m | |
Chief Operating Officer | 2yrs | US$2.77m | 0.045% $ 2.3m | |
Executive VP | 7.6yrs | US$2.34m | 0.048% $ 2.5m | |
President of Research & Development | 3.6yrs | US$2.81m | 0.045% $ 2.4m | |
Senior VP | 1.3yrs | no data | 0.024% $ 1.3m | |
Senior VP of Technical Operations and Chief Technical Operations & Quality Officer | 6.5yrs | US$3.79m | 0.055% $ 2.9m | |
Chief Scientific Officer | 2.9yrs | US$4.59m | 0.079% $ 4.2m | |
Senior Director & Head of Investor Relations | no data | no data | no data | |
Chief People Officer | 4.2yrs | no data | 0.043% $ 2.3m | |
Senior Vice President of Corporate Affairs | no data | no data | no data |
3.6yrs
Average Tenure
52yo
Average Age
Experienced Management: 2L9's management team is considered experienced (3.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2yrs | US$6.22m | 0.098% $ 5.2m | |
Co-Founder & Director | 13yrs | US$323.52k | 0.11% $ 6.0m | |
Member of Scientific Advisory Board | 11.9yrs | US$333.38k | no data | |
Lead Independent Director | 8yrs | US$373.59k | 0.014% $ 723.6k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board & Independent Director | 13yrs | US$348.45k | 0.087% $ 4.6m | |
Independent Director | 8.2yrs | US$346.39k | 0.014% $ 723.6k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 2.3yrs | US$326.51k | 0.0061% $ 321.2k | |
Chairman | 9.8yrs | US$1.59m | 0.24% $ 12.8m |
9.0yrs
Average Tenure
61yo
Average Age
Experienced Board: 2L9's board of directors are considered experienced (9 years average tenure).